Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech acquisition

This article was originally published in The Tan Sheet

Executive Summary

The Netherlands-based DSM Food Specialties, which develops ingredients for the food and beverage industries, strengthens its global position in food enzymes with the acquisition of U.S. biotechnology company Valley Research. Terms of the deal were not disclosed, but the acquisition has been finalized, DSM announces July 11. While strengthening its product portfolio, the deal also allows DSM to "offer regional blending and solution-providing platforms to customers," according to the firm. DSM provides enzymes and other ingredients and to food and beverage firms worldwide...

You may also be interested in...



Medtech Biggest Casualty In Swiss/EU Uncertainty As Worst Case Scenario Looms

Eighteen years of free trade threatens to crash, as a result of the stalemate in the market access agreement between Switzerland and the EU. Industry association Swiss Medtech is advising local medtech manufacturers to find notified bodies and authorized representatives based in the EU. However, local company SQS remains confident of its ongoing notified body role.

Interview: OurCrowd CEO Jon Medved On Israel’s Medtech “Boomtown”

With $1.3bn invested in over 200 high-tech start-ups, OurCrowd is now sharpening its focus on medtech. Medtech Insight spoke to founder Jon Medved to find out more.

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Topics

UsernamePublicRestriction

Register

PS101861

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel